Max Chat
Company Analysis 1Life Healthcare, Inc.
1. Summary
Advantages
- Price (16.47 $) is less than fair price (22.45 $)
- The stock's return over the last year (0%) is higher than the sector average (-1.3%).
- Current debt level 26.65% is below 100% and has decreased over 5 years from 31.94%.
Disadvantages
- Dividends (0%) are below the sector average (0.527%).
- The company's current efficiency (ROE=-24.31%) is lower than the sector average (ROE=14.17%)
Similar companies
2. Share price and performance
2.1. Share price
2.3. Market efficiency
| 1Life Healthcare, Inc. | Healthcare | Index | |
|---|---|---|---|
| 7 days | 0% | 0.4% | 0.1% |
| 90 days | 0% | 3.4% | 24.2% |
| 1 year | 0% | -1.3% | 11.6% |
ONEM vs Sector: 1Life Healthcare, Inc. has outperformed the "Healthcare" sector by 1.3% over the past year.
ONEM vs Market: 1Life Healthcare, Inc. has significantly underperformed the market by -11.57% over the past year.
Stable price: ONEM is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.
Long period: ONEM with weekly volatility of 0% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Below fair price: The current price (16.47 $) is lower than the fair price (22.45 $).
Price significantly below the fair price: The current price (16.47 $) is 36.3% lower than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (0) is lower than that of the sector as a whole (64.15).
P/E vs Market: The company's P/E (0) is lower than that of the market as a whole (90.03).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (2.12) is lower than that of the sector as a whole (18.96).
P/BV vs Market: The company's P/BV (2.12) is lower than that of the market as a whole (9.39).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (3.13) is lower than that of the sector as a whole (32.77).
P/S vs Market: The company's P/S indicator (3.13) is lower than that of the market as a whole (10.12).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (-14.12) is lower than that of the sector as a whole (274.79).
EV/Ebitda vs Market: The company's EV/Ebitda (-14.12) is lower than that of the market as a whole (50.91).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Rising and has grown by 69.7% over the last 5 years.
Earnings Slowdown: The last year's return (0%) is below the 5-year average return (69.7%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-15.75%).
5.4. ROE
ROE vs Sector: The company's ROE (-24.31%) is lower than that of the sector as a whole (14.17%).
ROE vs Market: The company's ROE (-24.31%) is lower than that of the market as a whole (11.64%).
5.5. ROA
ROA vs Sector: The company's ROA (-15.73%) is lower than that of the sector as a whole (1.18%).
ROA vs Market: The company's ROA (-15.73%) is lower than that of the market as a whole (6.89%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (-17.79%) is lower than that of the sector as a whole (7.63%).
ROIC vs Market: The company's ROIC (-17.79%) is lower than that of the market as a whole (11.08%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '0.527%.
7.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
8. Insider trades
8.1. Insider trading
Insider Buying Exceeds insider sales by 100% over the last 3 months.
8.2. Latest transactions
| Transaction date | Insider | Type | Price | Volume | Quantity |
|---|---|---|---|---|---|
| 17.02.2023 | Mango Lisa A General Counsel and Secretary |
Sale | 15.32 | 94 218 | 6 150 |
| 16.02.2023 | Mango Lisa A General Counsel and Secretary |
Sale | 15.36 | 116 675 | 7 596 |
| 16.02.2023 | Thaler Bjorn B Chief Financial Officer |
Sale | 15.36 | 92 390 | 6 015 |
| 16.02.2023 | Agarwal Vikas Chief Accounting Officer |
Sale | 15.36 | 32 517 | 2 117 |
| 24.10.2022 | Diamond Andrew S Chief Medical Officer |
Sale | 17.08 | 5 007 600 | 293 185 |
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
